GFAP and early-onset autosomal dominant Alzheimer disease: In addition, anti-glial fibrillar acid protein (GFAP) antibodies were also used as a marker of reactive gliosis, a phenomenon linked to numerous pathological conditions (infections, ischemia, and Alzheimer’s disease) and also linked to cases of traumatic injury [30].